Courtagen Life Sciences' rxSEEK Epilepsy
Courtagen Life Sciences has launched its rxSEEK Epilepsy genetic test to identify an individual’s susceptibility to adverse effects of anti-epileptic drugs. The next-generation sequencing-based test analyzes the DNA sequences of certain liver enzyme genes involved in drug metabolism associated with 24 different seizure medications.